STALLMACH, Andreas, Veli-Jukka ANTTILA, Markus HELL, Simon GWYNN, Paloma MERINO-AMADOR, Nicola PETROSILLO, Zdeněk RÁČIL, Tim WARREN, Christoph WENISCH and Mark WILCOX. Inflammatory bowel disease and Clostridium difficile infection: contrasting views of international clinical professionals. ZEITSCHRIFT FUR GASTROENTEROLOGIE. STUTTGART: GEORG THIEME VERLAG KG, 2018, vol. 56, No 7, p. 731-737. ISSN 0044-2771. Available from: https://dx.doi.org/10.1055/s-0044-100045.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Inflammatory bowel disease and Clostridium difficile infection: contrasting views of international clinical professionals
Authors STALLMACH, Andreas (276 Germany), Veli-Jukka ANTTILA (246 Finland), Markus HELL (40 Austria), Simon GWYNN (826 United Kingdom of Great Britain and Northern Ireland), Paloma MERINO-AMADOR (724 Spain), Nicola PETROSILLO (380 Italy), Zdeněk RÁČIL (203 Czech Republic, guarantor, belonging to the institution), Tim WARREN (826 United Kingdom of Great Britain and Northern Ireland), Christoph WENISCH (40 Austria) and Mark WILCOX (826 United Kingdom of Great Britain and Northern Ireland).
Edition ZEITSCHRIFT FUR GASTROENTEROLOGIE, STUTTGART, GEORG THIEME VERLAG KG, 2018, 0044-2771.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30219 Gastroenterology and hepatology
Country of publisher Germany
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 1.236
RIV identification code RIV/00216224:14110/18:00103950
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1055/s-0044-100045
UT WoS 000437861800016
Keywords in English inflammatory bowel disease; clostridium difficile infection; consensus report
Tags 14110212, rivok
Tags International impact, Reviewed
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 10/2/2019 14:51.
Abstract
Introduction In patients with inflammatory bowel disease (IBD), Clostridium difficile infection (CDI) is a risk factor for both morbidity and mortality. Currently, appropriate management is unclear. Guidance on best practice in the diagnosis and treatment of CDI in IBD patients is therefore needed. Methods A multidisciplinary group of clinicians involved in the treatment of patients with IBD and CDI developed 27 consensus statements. Respondents were asked to rate their agreement with each statement using a 4-point Likert scale. Amodified Delphi methodology was used to review responses of 442 physicians from different specialties (including infectious disease specialists [n = 104], microbiologists [n = 95], and gastroenterologists [n = 73]). A threshold of 75 % agreement was predefined as consensus. Results Consensus was achieved for 17 of the 27 statements. Unprompted recognition of risk factors for CDI was low. Intensification of immunosuppressive therapy in the absence of clinical improvement was controversial. Clear definitions of treatment failure of antibiotic therapy in CDI and recurrence of CDI in IBD are needed. Respondents require further clarity regarding the place of fecal microbiota transplantation in CDI patients with IBD. Differences were observed between the perceptions of microbiologists and gastroenterologists, as well as between countries. Conclusions Different perceptions both between specialties and geographical locations complicate the development of an internationally accepted algorithm for the diagnosis and treatment of CDI in patients with IBD. This study highlights the need for future studies in this area.
PrintDisplayed: 10/7/2024 05:12